Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

DSS, Inc. (DSS)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.2560-0.0085 (-3.21%)
At close: 04:00PM EDT
0.2672 +0.01 (+4.37%)
After hours: 06:10PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2645
Open0.2638
Bid0.2600 x 900
Ask0.2746 x 1100
Day's Range0.2500 - 0.2722
52 Week Range0.2500 - 1.3000
Volume166,715
Avg. Volume276,014
Market Cap20.415M
Beta (5Y Monthly)1.58
PE Ratio (TTM)0.82
EPS (TTM)0.3130
Earnings DateNov 16, 2022 - Nov 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • Zacks Small Cap Research

    DSS: DSS Plans Three Spin Offs in the Next Nine Months, With the First Potentially Worth $160 Million

    By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT Shareholders can look forward to three potential spin-offs at DSS (NYSE:DSS) in the next nine months. Investors are aware of the imminent spin-off of Impact Biomedical, as its red herring has been filed, and it is in the comments phase with the SEC. However, a spin-off of American Pacific Bancorp could actually happen more quickly as it

  • GlobeNewswire

    DSS Receives New York Stock Exchange Notice Regarding Late Form 10-Q Filing

    ROCHESTER, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced it received a notice (the "Notice") stating that the Company is not in compliance with the NYSE American’s continued listing requirements under the timely filing crit

  • GlobeNewswire

    Impact BioMedical Develops Quantum Antihistamine

    ROCHESTER, N.Y., July 26, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced that less than a year after successfully synthesizing its first Quantum-based compound, Impact Biomedical, Inc. and its research partner Global Research and Discovery

Advertisement
Advertisement